Since the elimination of the DEA x-waiver in January 2023, any clinician with a DEA license that includes Schedule III medication can now prescribe buprenorphine for the management of Opioid Use Disorder. This means more primary care providers can now utilize FDA-approved medication to help their patients living with OUD. But are those providers adequately equipped to meet the need and help turn the tide on the opioid epidemic? In this session, we hope to inspire integrated care teams to learn more about OUD and consider adding life-saving medication options to their integrated behavioral health skill set.
Kathy Ulivi FNP, BC, Family Medicine Nurse Practitioner, Morris Hospital,
University of Washington AIMS Center, Collaborative Care Implementation Guide and Evidence Base for CoCM, https://aims.uw.edu/evidence-base-for-cocm/
Collaborating to Heal Addiction and Mental Health in Primary Care: Clinical Trial Website, https://champ.psychiatry.uw.edu/
Casadonte, MD, Paul. (November 2021.),Buprenorphine Induction, Providers Clinical Support System. https://pcssnow.org/wp-content/uploads/2021/12/PCSS-GuidanceBuprenorphineInduction.Casadonte.pdf
Fortney,J. ( October 2023) Does Screening For Opioid Use Disorder in Primary Care Increase the Percentage of Patients with a New Diagnosis? Annals of Internal Medicine. https://www.acpjournals.org/doi/10.7326/M23-1369